Treatment
Infliximab
5
Conditions
584
Trials
101K
Participants
48%
Average Safety
Condition Evidence
Crohn's Disease
176 trials · 30K participants
75% effectiveness · 40% safety
Inflammatory bowel disease
259 trials · 50K participants
83% effectiveness · 55% safety
Interstitial lung disease and pulmonary sarcoidosis
30 trials · 800 participants
60% effectiveness · 35% safety
Pyoderma
1 trials · 500 participants
90% effectiveness · 48% safety
Ulcerative Colitis
118 trials · 20K participants
80% effectiveness · 60% safety